Site icon pharmaceutical daily

Pfizer cancels listing in the UK, U.S. FDA accept Inotuzamab submition for ALL in adults

Pfizer has decided to cancel listing of its stocks from the UK listing Authority List. The company said on Wednesday it cancels trading on the main London Stock Exchange market.

The company said it has limited trading or liquidity of its stocks on the Main Market of the LSE.

Pfizer also said it will leave the SIX Swiss Exchange, and will only continue to list its Common Stock on the New York Stock Exchange  under “PFE”.

Pfizer last traded on LSE at 16:35:55 on February 21, 2017 for the price of 33.65 and with the volume of 35, and the trade value of 1,177.75.

U.S. FDA OK’s Inotuzumab application

On Tuesday, the U.S. FDA accepted Pfizer’s submission for Inotuzumab Ozogamicin, for the treatment of refractory acute lymphoblastic leukemia (ALL) in adults. If the drug is approved, it will be a new treatment option for patients with relapsed B-cell precursor ALL.

The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in August 2017, Pfizer said.

In addition, a Marketing Authorization Application (MAA) for inotuzumab ozogamicin in the same patient population is currently under review by the European Medicines Agency (EMA).

Exit mobile version